Baiyunshan pharmacy branch gets approval for five drugs

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's branch, Baiyunshan Pharmaceutical General Factory, announced the receipt of supplementary application approvals for five drugs: Fukouan Tablets, Kunling Pills, Shenxidan, Yiganling Tablets, and Maian Granules. These approvals, issued by the National Medical Products Administration, update safety information and, for Fukouan Tablets, also modify specifications. The company estimates a total research and development investment of RMB 100,000 across these five projects.

Fukouan Tablets, for instance, generated RMB 27.74 million in the domestic market in 2024, with Baiyunshan Pharmaceutical General Factory contributing RMB 6.3754 million to that figure. Kunling Pills' domestic market sales reached RMB 13.15 million in 2024, though Baiyunshan Pharmaceutical General Factory did not market this product. Similarly, Shenxidan, a proprietary Chinese medicine, was not marketed by the branch in 2024. Yiganling Tablets saw domestic market sales of RMB 13.71 million in 2024, without Baiyunshan Pharmaceutical General Factory's market entry. Maian Granules recorded domestic sales of RMB 9.28 million in 2024, also without the branch's market presence.

These approvals are expected to improve the safety, efficacy, and rational use of these drugs, potentially boosting their market competitiveness. The company clarified that these approvals are not anticipated to have a significant impact on its current period's financial performance.